Thyroid hormones (THs) induce oncogenic signaling pathways involved in T cell lymphoma (TCL) progression

MERCEDES DEBERNARDI; DÍAZ ALBUJA JA; STERLE HA; PAULAZO A; DIAZ FLAQUE MARIA C; ROSEMBLIT C; CREMASCHI GA; CAYROL F

Buenos Aires

Congreso; SAFIS+ALACF 2021 joint meeting; 2021

THs influences tumor progression by direct actions on cancer cells, tumor microenvironment and the anti-tumor immunity. Our most recent results indicate that THs, acting via integrin αVβ3, promotes cell proliferation, survival and induces an angiogenic program in TCL cells. These lymphoproliferative disorders are very aggressive, and the available therapeutic regimens have poor results, with a high rate of relapses and few effective options for rescue therapy. The understanding of the molecular mechanisms of THs actions in malignant cells could lead to the identification of new therapeutic targets. The main aim of this work was to evaluate the effect of THs on the oncogenic intracellular pathways that influence lymphoma progression and were found dysregulated in most of TCL patients. For this propose we analyzed TCL cell lines corresponding to immature (CUTLL1) and mature (OCI-Ly12, OCI-Ly13.2) human subtypes after 10, 15 and 30 minutes THs treatment. We found that physiological concentrations of THs significantly increase STAT1, 3 and 5 phosphorylation in both CUTLL1 and LY13.2 (p